(Washington, D.C.) — As part of its OnYourRxSide campaign, the Pharmaceutical Care Management Association (PCMA) today released a new video — “What is a PBM?” — detailing the role pharmacy benefit managers (PBMs) play in the prescription drug supply chain
(Washington, D.C.) — New data from the National Council for Prescription Drug Programs (NCPDP) database, highlighted today by the Pharmaceutical Care Management Association (PCMA), shows that the independent retail pharmacy market in the United States is stable. Over the last 10 years,
Unlocking an Affordable Future: Key #2 Support and Equip Clinicians SUPPORT AND EQUIP CLINICIANS WITH TOOLS AND DATA TO SERVE PATIENTS OPTIMALLY Physicians, pharmacists, and other health care providers are valued employees within pharmacy benefit companies and esteemed healthcare partners outside
Conversation on “Improving Competition to Lower Drug Prices” Emphasizes Need to Stop Abuse of the Patent System Last week, The Hill hosted an event titled, “Prescription for Change: Improving Competition to Lower Drug Prices.” During the event, lawmakers and a panel of drug
PBMs: Committed to Helping Patients The Critical Path Forward: Rx Policies to Reduce Patient Costs, Improve Access For America’s pharmacy benefit managers, PBMs, our core mission is to increase access to affordable prescription drugs for all Americans. But more can
(Washington, D.C.) — In honor of World Diabetes Day, the Pharmaceutical Care Management Association (PCMA) has launched a new phase of the OnYourRxSide campaign that showcases how pharmacy benefit managers, PBMs, are working to improve the lives of patients living
May is Asthma Awareness Month, and today – May 5 – is World Asthma Day. The Asthma and Allergy Foundation of America is marking the day with the release of their 2021 Asthma Capitals Report.
A wide array of voices from across the country are calling on lawmakers to oppose recently reintroduced legislation, the Pharmacy Benefit Manager Transparency Act (S.127), which fundamentally misconstrues the role of pharmacy benefit companies, unfairly proposes to take away employers’
Makers of brand-name drugs called out by the Trump administration for potentially stalling generic competition have hiked their prices by double-digit percentages since 2012 and cost Medicare and Medicaid nearly $12 billion in 2016, a Kaiser Health News analysis has
As Congress considers anti-PBM legislation in the new year, it is important lawmakers are aware that allowing the government to dictate the winners and losers in the health care system, according to policymakers and experts, will do nothing to actually
©2024 PCMA. All Rights Reserved.
